Vivior has developed the Vivior Monitor – the first “Fitbit for the eyes”!
Early-bird bonus +1% base-interest until 22.10!
€ 2.5 m
€ 12.5 m
3.0% base-interest p.a. + full participation in increase of company value
Legal warning: The acquisition of this investment is associated with considerable risks and may lead to the complete loss of the invested assets. The promised return is not guaranteed and may also be lower.
The Vivior monitor is a lightweight, user-friendly device for objective measurement of visual behavior.
Founded in 2017 out of Zurich, Vivior AG now uses AI activity recognition as well as visual behavioral assessment to objectively and accurately determine the best lenses for patients’ and customers’ specific needs.
Strong starting position
Vivior AG has already invested € 5.9 m and today the company already has an existing customer base of more than 100 B2B customers, including leading companies in the field of ophthalmic optics and ophthalmology.
What's the catch? We are still searching today.
Run by specialists
Founded at that time by 5 experienced specialists, today the team consists of a globally recognized medical advisory board and a team of 9 experienced employees.
Lucrative business model
The business model consists of recurring user fees for the use of the device and data analysis. In this context, the solution is aimed at all end users who need a visual aid. Target groups are:
- Eye specialists: ophthalmologists, optometrists, opticians
- Digital health platforms
Financial planning with break-even in 2024
Planned sales are approximately €30 m for 2024. In the long term, Vivior projects an EBIT margin of >25%.
What makes Vivior unique?
Vivior is the only solution that links eye health with objective data on vision behavior, enabling eye care professionals, optometrists and opticians to find the optimal vision solution for better vision, well-being and health.
Multiple application fields
Vivior addresses its product to a sufficiently large market: the market for visual aids in general is €165 billion, the premium segment of which is $17 billion, and the market for ophthalmic diagnostic devices is still $1.7 billion.
Fully personalized vision correction services based on the real needs of each patient’s daily life.
Vivior Myopia Analysis, which helps parents better understand their children’s myopia risk and manage long-term vision and eye health.
Personalized applications to improve visual performance for better results in recreational activities leading to a better lifestyle and overall health.
Digital office health
Vivior workplace analysis to reduce the physical and psychological effects of computer vision syndrome, including neck and shoulder pain, headaches and eye strain.
Great potential for the future
Through cross-sector partnerships and the provision of solutions for "Digital Health in the Office", Vivior creates a promising environment for versatile opportunities for success. Specific plans for the technology, telemedicine, insurance, ECPs (eye-care professionals) and large enterprise sectors in general promise high revenue growth.
Entrepreneurs with excellent track records, accompanied by a scientific advisory board of leading European researchers.
Prof. Michael Mrochen, Ph.D.
- Serial entrepreneur with previous exits (Avedro; IROC Innocross, Clear Sight Innovations; Alcon)
- Globally recognized scientist
- Created hundreds of millions of $ in shareholder value through innovative products
Pavel Zakharov, Ph.D.
- PhD in biomedical optics and laser biophysics
- Technological expert in several startups focusing on innovative medical sensor technology and wearable monitoring devices
Mario Stark, MA
- Experience as CEO of several startups
- Executive in large medical device companies
- Board member of several startups in the medical device, wearable sensor and digital health industries
Paul J. Soye, Ph.D., MBA
- Former global head of cataract surgery research and development at Alcon, based in Fort Worth, TX, USA
- Founder of Hibernian Consulting LLC
Board of Directors
In addition to the Board of Directors, Vivior has a Medical Advisory Board, a Scientific Advisory Board and a Health Advisory Board consisting of internationally recognized experts.
Vivior AG Contact & Legal Notice
Notice under Section 12 (2) & (3) of the German Investment Act (Vermögensanlagengesetz)
The acquisition of this investment is associated with considerable risks and may lead to the complete loss of the invested assets. The promised return is not guaranteed and may also be lower. aescuvest GmbH does not guarantee that reported interest will actually be achieved.
More information can be found under risk information.